Abstract

MicroPET imaging studies using 18F-nifene, a new positron emission tomography (PET) radiotracer for nicotinic acetylcholinergic receptors (nAChR) α4β2 receptors in rats, have been carried out. Rats were imaged for 90 min after intravenous injection of 18F-nifene (0.8 to 1 mCi), and binding potential (BPND) was measured. 18F-Nifene binding to thalamic and extrathalamic brain regions was consistent with the α4β2 nAChR distribution in the rat brain. Using the cerebellum as a reference, the values for the thalamus varied less than 5% (BPND = 1.30, n = 3), confirming reproducibility of 18F-nifene binding. 18F-Nifene microPET imaging was also used to evaluate effects of nicotine in a group of Sprague-Dawley rats under isoflurane anesthesia. Nicotine challenge postadministration of 18F-nifene demonstrated reversibility of 18F-nifene binding in vivo. For α4β2 nAChR receptor occupancy (nAChROCC), various doses of nicotine (0, 0.02, 0.1, 0.25, and 0.50 mg/kg nicotine free base) 15 min prior to 18F-nifene were administered. Low-dose nicotine (0.02 mg) reached > 80% nAChROCC while at higher doses (0.25 mg) > 90% nAChROCC was measured. The small amount of 18F-nifene binding with reference to the cerebellum affects an accurate evaluation of nAChROCC. Efforts are underway to identify alternate reference regions for 18F-nifene microPET studies in rodents.

Highlights

  • Nicotinic a4b2 receptors play an important role in many CNS disorders such as Alzheimer’s disease, Parkinson’s disease, Schizophrenia, mood disorders, and nicotine dependence

  • We have developed 18F-nifene (2-18F-fluoro-3-[2-((S)-3-pyrrolinyl) methoxy]pyridine; Figure 1), a nicotinic a4b2 receptor agonist which is suitable for positron emission tomography (PET) imaging (Ki = 0.50 nM; [2,3])

  • MicroPET 18F-nifene binding studies A rapid uptake of 18F-nifene was observed in the brain with levels of approximately 1% of injected dose per cubic centimeter

Read more

Summary

Introduction

Nicotinic a4b2 receptors play an important role in many CNS disorders such as Alzheimer’s disease, Parkinson’s disease, Schizophrenia, mood disorders, and nicotine dependence. Much work is being done on radiotracer compounds with high binding affinity as well as faster kinetics which can be used as an aid to visualize the nicotinic receptors and their involvement in neurological disorders [1]. Both 5-123I-iodo-A-85380 and 2-18F-fluoro-A-85380 have a high affinity for the a4b2 receptors with scan times exceeding several hours. We have developed 18F-nifene (2-18F-fluoro-3-[2-((S)-3-pyrrolinyl) methoxy]pyridine; Figure 1), a nicotinic a4b2 receptor agonist which is suitable for positron emission tomography (PET) imaging (Ki = 0.50 nM; [2,3]). Imaging times in nonhuman primates with 18F-nifene [2] were reduced significantly compared to 18F-flouroA-85380 [4]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.